 Connection
David Fox to Transforming Growth Factor beta
This is a "connection" page, showing publications David Fox has written about Transforming Growth Factor beta.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.171 |
|
|
|
-
Fechtner S, Fox DA, Ahmed S. Transforming growth factor ß activated kinase 1: a potential therapeutic target for rheumatic diseases. Rheumatology (Oxford). 2017 07 01; 56(7):1060-1068.
Score: 0.106
-
Muraoka S, Brodie WD, Mattichak MN, Gurrea-Rubio M, Ikari Y, Foster C, Amin MA, Khanna N, Amin H, Campbell PL, Vichaikul S, Model EN, Omara MM, Petrovski S, Kozicki K, Amarista C, Webber A, Ali M, Palisoc PJ, Hervoso J, Ruth JH, Tsoi LC, Varga J, Gudjonsson JE, Khanna D, Fox DA, Tsou PS. Targeting CD13/Aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis. Arthritis Rheumatol. 2025 Jan; 77(1):80-91.
Score: 0.044
-
Haak AJ, Tsou PS, Amin MA, Ruth JH, Campbell P, Fox DA, Khanna D, Larsen SD, Neubig RR. Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury. J Pharmacol Exp Ther. 2014 Jun; 349(3):480-6.
Score: 0.021
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|